Article citationsMore>>

Glueck, C.J., Fontaine, R.N., Wang, P., Subbiah, M.T.R., Weber, K., Illig, E., et al. (2001) Metformin reduces weight, centropedal obesity, insulin, leptin, and low-density lipoprotein cholesterol in non-diabetic, morbidly obese subjects with body mass index greater than 30. Metabolism, 50, 856-861. doi:10.1053/meta.2001.24192

has been cited by the following article:

• TITLE: Dose-dependent relationship between serum metformin levels and glycemic control, insulin resistance and leptin levels in females newly diagnosed with type 2 diabetes mellitus

  AUTHORS: Kadhim Ali Kadhim, Dowser Khalil Ismael, Ban Hoshi Khalaf, Khalid Ibrahim Hussein, Munaf Hashim Zalzala, Saad Abdulrahman Hussain

  KEYWORDS: Type2 Diabetes Mellitus; Leptin; BMI; Serum Metformin; Glycemic Control

  JOURNAL NAME: Journal of Diabetes Mellitus, Vol.2 No.2, May 25, 2012

  ABSTRACT: Despite the extensive clinical experience with the use of metformin worldwide, no formal dose-ranging study has been conducted because the current dosing strategy of metformin was determined empirically, rather than by an understanding of its dose-response relationship in patients with type 2 diabetes. The present study was designed to evaluate the correlation between serum metformin levels and glycemic control, insulin resistance and leptin levels in females newly diagnosed with type 2 diabetes. Sixty type 2 diabetic females were recruited for the study and were allocated into 3 groups; each receiving metformin 1000, 1500 and 2000 mg/day respectively for 3 months. Blood samples withdrawn from each patient at zero time and after 3 months is used to evaluate serum levels of HbA1c, glucose, leptin and insulin, in addition, the measurement of serum level of metformin in blood after 3 months by HPLC. The results demonstrated that all the treated groups with different doses of metformin showed significant improve in all parameters; the use of increased metformin doses was only correlated with plasma leptin levels in the highest dose. In conclusion, serum metformin levels are not good predictors for correlating improvement in clinical and biochemical parameters with increasing the dose in newly diagnosed non-insulin resistant females with type 2 diabetes.